



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

NOV 13 1991

#11

Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fisher's Lane, Room 11-44
Rockville, MD 20857

Dear Mr. Wilson:

The enclosed application for patent term extension of U.S. Patent No. 4,242,334 issued on December 30, 1980, was filed on November 12, 1991, under 35 USC § 156.

Your assistance is requested in confirming that the product identified in the application has been subject to a regulatory review period within the meaning of 35 USC § 156 (g) before its commercial marketing or use. Since a determination has not been made whether the patent in question claims a product which is subject to the Federal Food, Drug and Cosmetic Act, this communication is **NOT** to be considered as notice which may be made in the future pursuant to 35 USC § 156 (d) (2) (A).

Our review of the application to date indicates that the subject matter would be eligible for extension of the patent term under 35 USC § 156.

C. E. Van Horn

Charles E. Van Horn
Patent Policy & Programs Administrator
Office of the Assistant Commissioner for Patents

cc: Tatsuya Ikeda
Hoechst Celanese Corp., Patent Dept.
Route 202-206, P.O. Box 2500
Somerville, NJ 08876-1258